U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H33NO2.ClH
Molecular Weight 391.975
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NE-100

SMILES

Cl.CCCN(CCC)CCC1=CC=C(OC)C(OCCC2=CC=CC=C2)=C1

InChI

InChIKey=ZHGMDXSHODHWHV-UHFFFAOYSA-N
InChI=1S/C23H33NO2.ClH/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20;/h6-12,19H,4-5,13-18H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C23H33NO2
Molecular Weight 355.5136
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19053780 | https://www.ncbi.nlm.nih.gov/pubmed/18774292 | https://www.ncbi.nlm.nih.gov/pubmed/15322732

NE-100 is potent and selective σ1 receptor antagonist that displays > 55-fold selectivity over σ2receptors and > 6000-fold selectivity over D1, D2, 5-HT1A, 5-HT2 and PCP receptors. NE-100 exhibits reversible binding and displays antipsychotic activity in vivo.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.03 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.
2008 Oct 1
Patents

Patents

Sample Use Guides

Male and female beagle dogs (7.5 - 13.5 kg) were placed individually in a cage (70 x 70 x 70 cm). NE-100 (0.03, 0.1 and 0.3 mg/kg) was given orally 10 min before the administration of PCP (0.6 mg/kg, s.c.), then the animals were observed for abnormal behavior every 10 min for 60 min. Abnormal behavior was scored according to the following criteria.
Route of Administration: Oral
Cells were seeded into 96-well plates for optical performance in the fluorescent cell-based assay in 100 μl complete medium in the presence or absence of different concentrations of NE-100. The plate was incubated for 24 h in a humidified atmosphere 5% CO2 at 37°C and then 100 μl substrate mix in assay buffer added. A 10 μl aliquot of lysis solution was added to untreated wells to estimate total LDH. Plates were kept protected from light for 10 min at room temperature, and then 50 μl stop solution was added to all wells. The fluorescence was recorded using a LS55 Luminescence Spectrometer Perkin Elmer (excitation at 560 nm; emission at 590 nm).
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:57:49 GMT 2023
Edited
by admin
on Sat Dec 16 15:57:49 GMT 2023
Record UNII
T6QLY532R9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NE-100
Code English
4-METHOXY-3-(2-PHENYLETHOXY)-N,N-DIPROPYLBENZENEETHANAMINE HYDROCHLORIDE (1:1)
Systematic Name English
NE 100
Code English
BENZENEETHANAMINE, 4-METHOXY-3-(2-PHENYLETHOXY)-N,N-DIPROPYL-, HYDROCHLORIDE
Systematic Name English
BENZENEETHANAMINE, 4-METHOXY-3-(2-PHENYLETHOXY)-N,N-DIPROPYL-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
T6QLY532R9
Created by admin on Sat Dec 16 15:57:49 GMT 2023 , Edited by admin on Sat Dec 16 15:57:49 GMT 2023
PRIMARY
PUBCHEM
9952420
Created by admin on Sat Dec 16 15:57:49 GMT 2023 , Edited by admin on Sat Dec 16 15:57:49 GMT 2023
PRIMARY
CAS
149409-57-4
Created by admin on Sat Dec 16 15:57:49 GMT 2023 , Edited by admin on Sat Dec 16 15:57:49 GMT 2023
PRIMARY
CHEBI
140905
Created by admin on Sat Dec 16 15:57:49 GMT 2023 , Edited by admin on Sat Dec 16 15:57:49 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE